V
91.53
1.45 (1.61%)
| Previous Close | 90.08 |
| Open | 90.27 |
| Volume | 435,795 |
| Avg. Volume (3M) | 1,364,760 |
| Market Cap | 7,778,118,144 |
| Price / Sales | 63.78 |
| Price / Book | 34.39 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -138.31% |
| Operating Margin (TTM) | -13.53% |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 107.63% |
| Current Ratio (MRQ) | 8.86 |
| Operating Cash Flow (TTM) | -120.15 M |
| Levered Free Cash Flow (TTM) | -69.15 M |
| Return on Assets (TTM) | -20.64% |
| Return on Equity (TTM) | -72.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Verona Pharma plc | Bearish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | -0.38 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.40% |
| % Held by Institutions | 90.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Mar 2025 | 3,923,204 |
| Vivo Capital, Llc | 31 Mar 2025 | 1,438,785 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 170.00 (Wolfe Research, 85.73%) | Buy |
| Median | 111.50 (21.82%) | |
| Low | 90.00 (HC Wainwright & Co., -1.67%) | Buy |
| Average | 123.50 (34.93%) | |
| Total | 6 Buy, 2 Hold | |
| Avg. Price @ Call | 91.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 09 Jul 2025 | 107.00 (16.90%) | Hold | 91.53 |
| Jefferies | 09 Jul 2025 | 107.00 (16.90%) | Hold | 91.53 |
| 11 Jun 2025 | 110.00 (20.18%) | Buy | 90.05 | |
| Wolfe Research | 01 Jul 2025 | 170.00 (85.73%) | Buy | 90.48 |
| Piper Sandler | 23 Jun 2025 | 160.00 (74.81%) | Buy | 97.05 |
| Wells Fargo | 20 Jun 2025 | 138.00 (50.77%) | Buy | 94.32 |
| 30 Apr 2025 | 107.00 (16.90%) | Buy | 72.07 | |
| Roth Capital | 18 Jun 2025 | 116.00 (26.73%) | Buy | 90.92 |
| Cantor Fitzgerald | 11 Jun 2025 | 100.00 (9.25%) | Buy | 90.05 |
| HC Wainwright & Co. | 02 Jun 2025 | 90.00 (-1.67%) | Buy | 84.10 |
| 30 Apr 2025 | 85.00 (-7.13%) | Buy | 72.07 | |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |